1. Home
  2. ENTG vs BBIO Comparison

ENTG vs BBIO Comparison

Compare ENTG & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Entegris Inc.

ENTG

Entegris Inc.

HOLD

Current Price

$111.92

Market Cap

17.0B

Sector

Industrials

ML Signal

HOLD

Logo BridgeBio Pharma Inc.

BBIO

BridgeBio Pharma Inc.

HOLD

Current Price

$69.75

Market Cap

15.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ENTG
BBIO
Founded
1966
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Plastic Products
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
17.0B
15.3B
IPO Year
2000
2019

Fundamental Metrics

Financial Performance
Metric
ENTG
BBIO
Price
$111.92
$69.75
Analyst Decision
Buy
Strong Buy
Analyst Count
11
25
Target Price
$127.80
$83.96
AVG Volume (30 Days)
1.9M
1.8M
Earning Date
05-06-2026
04-28-2026
Dividend Yield
0.35%
N/A
EPS Growth
N/A
N/A
EPS
1.55
N/A
Revenue
$3,196,600,000.00
$502,076,000.00
Revenue This Year
$9.27
$88.16
Revenue Next Year
$9.39
$74.13
P/E Ratio
$74.83
N/A
Revenue Growth
N/A
126.26
52 Week Low
$60.75
$28.33
52 Week High
$142.50
$84.94

Technical Indicators

Market Signals
Indicator
ENTG
BBIO
Relative Strength Index (RSI) 42.71 48.95
Support Level $108.02 $61.95
Resistance Level $124.00 $78.83
Average True Range (ATR) 5.28 3.02
MACD -0.15 0.39
Stochastic Oscillator 27.85 24.66

Price Performance

Historical Comparison
ENTG
BBIO

About ENTG Entegris Inc.

Entegris is a leading supplier of purification solutions and advanced materials. The vast majority of sales are to the semiconductor industry. The majority of revenue comes from semiconductor fabricators, but the company sells to all areas of the semiconductor manufacturing supply chain including equipment and engineering, chemicals and materials, and distributors. Entegris specializes in materials science and materials purity, both of which are crucial in the semiconductor manufacturing process.

About BBIO BridgeBio Pharma Inc.

BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.

Share on Social Networks: